InsiderSignalSign in

← Insider buys

RYTM

Rhythm Pharmaceuticals, Inc. · Healthcare

Insiders sold $36.4M of Rhythm Pharmaceuticals, Inc. in the last 12 months and bought none

$0Bought, 12 mo

$36.4MSold, 12 mo

$5.9BMarket cap

RYTM over the last year

No insider buys filed in this year

RYTM after insider buys

3 months after each buy, from the first price a copier could get.

No buys have 3 months of prices yet. A record shows here at 3.

Every filing

121 insider filings since 2017, newest first

David P Meeker · President and CEO

$5.1M−17.3%Sep 14

Hunter C Smith · Chief Financial Officer

$6.6M−35.5%Sep 1

Joseph Shulman · Chief Technical Officer

$608K−24.2%Aug 17

Alastair Garfield · Chief Scientific Officer

$913K−77.2%Aug 17

Jennifer Kayden Lee · EVP, Head of North America

$8.9M−100.0%Aug 14

Yann Mazabraud · EVP, Head of International

$6.6M−50.6%Aug 14

Lynn A. Tetrault · Director

$3.7M−84.1%Jun 24

Christopher Paul German · Corporate Controller, CAO

$428K−100.0%May 19

Christopher Paul German · Corporate Controller, CAO

$503K−97.0%Mar 6

Hunter C Smith · CFO

$806K−7.0%Feb 19

Hunter C Smith · CFO

$709K−6.0%Feb 12

Hunter C Smith · CFO

$703K−5.0%Feb 6

Pamela J. Cramer · CHRO

$372K−14.0%Dec 15

Pamela J. Cramer · CHRO

$352K−14.0%Nov 24

Jennifer Kayden Lee · EVP, Head of North America

$4.4M−99.0%Nov 13

Joseph Shulman · Chief Technical Officer

$882K−100.0%Nov 13

Pamela J. Cramer · CHRO

$586K−41.0%Nov 8

Jennifer L Good · Director

$1.7M−91.0%Sep 19

Pamela J. Cramer · CHRO

$205K−23.0%Sep 11

Lynn A. Tetrault · Director

$1.0M−87.0%Sep 11

Jennifer L Good · Director

$1.9M−93.0%Sep 11

Pamela J. Cramer · CHRO

$160K−19.0%Aug 28

Lynn A. Tetrault · Director

$215K−59.0%Aug 28

Jennifer L Good · Director

$726K−83.0%Aug 28

Lynn A. Tetrault · Director

$446K−77.0%Aug 14

Pamela J. Cramer · CHRO

$2.2M−78.0%Aug 13

Pamela J. Cramer · CHRO

$68K−4.0%Jul 30

Joseph Shulman · Chief Technical Officer

$555K−100.0%Jul 18

Joseph Shulman · Chief Technical Officer

$266K−99.0%Jul 16

Joseph Shulman · Chief Technical Officer

$153K−99.0%May 13

Joseph Shulman · Chief Technical Officer

$736K−100.0%Mar 22

Jennifer Kayden Lee · EVP, Head of North America

$707K−73.0%Mar 22

Yann Mazabraud · EVP, Head of International

$628K−40.0%Mar 19

Hunter C Smith · CFO

$608K−14.0%Mar 19

Joseph Shulman · Chief Technical Officer

$608K−46.0%Mar 19

David P Meeker · President and CEO

$1.8M−21.0%Mar 19

Jennifer Kayden Lee · EVP, Head of North America

$608K−38.0%Mar 19

Pamela J. Cramer · CHRO

$608K−34.0%Mar 19

Joseph Shulman · Chief Technical Officer

$148K−99.0%Feb 15

Yann Mazabraud · EVP, Head of International

$130K−27.0%Feb 13

Hunter C Smith · CFO

$97K−2.0%Feb 13

Jennifer Kayden Lee · EVP, Head of North America

$83K−19.0%Feb 13

Joseph Shulman · Chief Technical Officer

$3.7M−96.0%Feb 13

Pamela J. Cramer · CHRO

$36K−6.0%Feb 13

Jennifer Kayden Lee · EVP, Head of North America

$67K−33.0%Feb 5

Hunter C Smith · CFO

$73K−2.0%Feb 5

Joseph Shulman · Chief Technical Officer

$60K−34.0%Feb 5

David P Meeker · President and CEO

$197K−3.0%Feb 5

Pamela J. Cramer · CHRO

$43K−9.0%Feb 5

Joseph Shulman · Chief Technical Officer

$647K−100.0%Dec 29

About Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.